Loading
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
  • Login
    • Password Reset
  • Register
(852) 3008 1717
Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong Kong
  • Health
  • Digital Marketing
  • Medical Writing
  • Contact Us
    • Request Quote
  • Search
  • Menu
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

Conference Support

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology


Medical Writer: Stijn van den Borne, MSc
Updated: 11 September 2017

Our Experience

YOU MAY ALSO LIKE

Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

https://medi-paper.com/wp-content/uploads/2018/11/Meta-analysis-TIVA-with-propofol-lowers-post-operative-nausea-vomiting-and-pain.jpg 861 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Anaesthesiology.asia2018-11-27 15:43:582018-11-28 10:18:56Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain
Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy©MediPaper Medical Communications Ltd

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

https://medi-paper.com/wp-content/uploads/2018/11/Intraperitoneal-bupivacaine-to-reduce-postoperative-opioid-use-following-laparoscopic-appendectomy.jpg 1000 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Anaesthesiology.asia2018-11-22 12:43:272018-11-22 12:51:37Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy
ASPEN CSA 2017 Prof Xue Zhanggang on TIVA Enhanced Recovery by Optimized Anesthetics

TIVA: enhanced recovery by optimized anesthetics

https://medi-paper.com/wp-content/uploads/2017/11/ASPEN-CSA-2017-Prof-Xue-Zhanggang-on-TIVA-Enhanced-Recovery-by-Optimized-Anesthetics.jpeg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-23 16:06:422018-09-26 11:37:43TIVA: enhanced recovery by optimized anesthetics
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

https://medi-paper.com/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.jpg 687 1030 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-07 22:23:132018-09-26 11:38:14CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China
PreviousNext

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology.

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology (CSA), held from 7-10 September 2017 in Zhengzhou, Henan Province, PR China.

We would like to extend our gratitude to the inviting partner, the CSA, and doctors for making time to meet our medical writer.

The Annual Meeting of the CSA, the official anaesthetist chapter of the Chinese Medical Association, is the largest anaesthesiology meeting in China.

  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
PreviousNext
123456789

© Copyright 2017 – MediPaper – 25th Annual Meeting of the Chinese Society of Anaesthesiology – CSA2017 – 中华医学会第25 次全国麻醉学术年会

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

You may also like

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-12-11 13:21:272018-12-11 13:22:23Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 11-Dec-2018

https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-12-11 08:00:012018-12-11 15:30:45US FDA approved immune-checkpoint inhibitors updated 11-Dec-2018
MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

https://medi-paper.com/wp-content/uploads/2018/12/Depositphotos_159314198_xl-2015.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-12-05 22:00:342018-12-13 13:22:27MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab
TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

https://medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy
Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

Efficacy of oral Cladribine for MS durable after a two-year treatment course

https://medi-paper.com/wp-content/uploads/2018/12/Efficacy-of-Oral-Cladribine-in-Multiple-Sclerosis-Durable-after-a-2-Year-Course-of-Treatment.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-12-03 17:05:442018-12-03 17:21:47Efficacy of oral Cladribine for MS durable after a two-year treatment course

Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-11-29 15:08:432018-11-29 15:11:38Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-11-28 17:00:152018-11-28 18:03:05TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion
Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

https://medi-paper.com/wp-content/uploads/2018/11/Meta-analysis-TIVA-with-propofol-lowers-post-operative-nausea-vomiting-and-pain.jpg 861 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Anaesthesiology.asia2018-11-27 15:43:582018-11-28 10:18:56Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png News Feed2018-11-23 23:17:102018-11-23 23:24:03Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
PreviousNext
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2017 – MediPaper – CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology

Therapeutic Areas

Get access to restricted content via WeChat

MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港 Wechat

Newsletter

 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | Medical Communications Health Blog | Medical Writer Jobs | MediNews.asia | Anaesthesiology.asia
© 2016-2018 MediPaper Medical Communications Ltd | Medical Writer Hong Kong | 醫學寫作 | 醫學作家香港 | Privacy Policy | Terms of Service | Cookie Policy
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
Latest global trends of health measure and impact on survival rate Latest global trends of health measure and impact on survival rate Nivolumab Renal Cell Cancer Symposium Highlight Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com

Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds: